[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2009043889A3 - Oxadiazole derivatives - Google Patents

Oxadiazole derivatives Download PDF

Info

Publication number
WO2009043889A3
WO2009043889A3 PCT/EP2008/063180 EP2008063180W WO2009043889A3 WO 2009043889 A3 WO2009043889 A3 WO 2009043889A3 EP 2008063180 W EP2008063180 W EP 2008063180W WO 2009043889 A3 WO2009043889 A3 WO 2009043889A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxadiazole derivatives
compounds
useful
formula
treatment
Prior art date
Application number
PCT/EP2008/063180
Other languages
French (fr)
Other versions
WO2009043889A2 (en
Inventor
Anna Quattropani
Cyril Montagne
Wolfgang Sauer
Stefano Crosignani
Agnes Bombrun
Mathilde Muzerelle
Jerome Dorbais
Delphine Marin
Jerome Gonzalez
Patrick Gerber
Original Assignee
Merck Serono Sa
Anna Quattropani
Cyril Montagne
Wolfgang Sauer
Stefano Crosignani
Agnes Bombrun
Mathilde Muzerelle
Jerome Dorbais
Delphine Marin
Jerome Gonzalez
Patrick Gerber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2010527449A priority Critical patent/JP6144450B2/en
Priority to ES08804970.5T priority patent/ES2622423T3/en
Priority to CA2696863A priority patent/CA2696863C/en
Priority to EA201070422A priority patent/EA201070422A1/en
Priority to EP08804970.5A priority patent/EP2193125B1/en
Priority to CN200880110421.2A priority patent/CN101970420B/en
Priority to MX2010003612A priority patent/MX2010003612A/en
Priority to BRPI0818457 priority patent/BRPI0818457A2/en
Application filed by Merck Serono Sa, Anna Quattropani, Cyril Montagne, Wolfgang Sauer, Stefano Crosignani, Agnes Bombrun, Mathilde Muzerelle, Jerome Dorbais, Delphine Marin, Jerome Gonzalez, Patrick Gerber filed Critical Merck Serono Sa
Priority to AU2008306885A priority patent/AU2008306885B2/en
Priority to US12/675,235 priority patent/US8202865B2/en
Publication of WO2009043889A2 publication Critical patent/WO2009043889A2/en
Publication of WO2009043889A3 publication Critical patent/WO2009043889A3/en
Priority to ZA2010/01121A priority patent/ZA201001121B/en
Priority to IL204521A priority patent/IL204521A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

The invention relates to compounds of formula (I). The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
PCT/EP2008/063180 2007-10-04 2008-10-01 Oxadiazole derivatives WO2009043889A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MX2010003612A MX2010003612A (en) 2007-10-04 2008-10-01 Oxadiazole derivatives.
CA2696863A CA2696863C (en) 2007-10-04 2008-10-01 Oxadiazole derivatives
EA201070422A EA201070422A1 (en) 2007-10-04 2008-10-01 OXADIAZOL DERIVATIVES
EP08804970.5A EP2193125B1 (en) 2007-10-04 2008-10-01 Oxadiazole derivatives
CN200880110421.2A CN101970420B (en) 2007-10-04 2008-10-01 Oxadiazole Derivatives
JP2010527449A JP6144450B2 (en) 2007-10-04 2008-10-01 Oxadiazole derivatives
US12/675,235 US8202865B2 (en) 2007-10-04 2008-10-01 Oxadiazole derivatives
BRPI0818457 BRPI0818457A2 (en) 2007-10-04 2008-10-01 OXADIAZOL DERIVATIVES
AU2008306885A AU2008306885B2 (en) 2007-10-04 2008-10-01 Oxadiazole derivatives
ES08804970.5T ES2622423T3 (en) 2007-10-04 2008-10-01 Oxadiazole Derivatives
ZA2010/01121A ZA201001121B (en) 2007-10-04 2010-02-16 Oxadiazole derivatives
IL204521A IL204521A0 (en) 2007-10-04 2010-03-16 Oxadiazole derivatives, their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07117921.2 2007-10-04
EP07117921 2007-10-04
US99825407P 2007-10-09 2007-10-09
US60/998,254 2007-10-09

Publications (2)

Publication Number Publication Date
WO2009043889A2 WO2009043889A2 (en) 2009-04-09
WO2009043889A3 true WO2009043889A3 (en) 2009-08-20

Family

ID=38984441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/063180 WO2009043889A2 (en) 2007-10-04 2008-10-01 Oxadiazole derivatives

Country Status (15)

Country Link
US (1) US8202865B2 (en)
EP (1) EP2193125B1 (en)
JP (2) JP6144450B2 (en)
KR (1) KR20100075608A (en)
CN (1) CN101970420B (en)
AR (1) AR068731A1 (en)
AU (1) AU2008306885B2 (en)
BR (1) BRPI0818457A2 (en)
CA (1) CA2696863C (en)
EA (1) EA201070422A1 (en)
ES (1) ES2622423T3 (en)
IL (1) IL204521A0 (en)
MX (1) MX2010003612A (en)
WO (1) WO2009043889A2 (en)
ZA (2) ZA201001121B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3345895T3 (en) 2003-04-11 2020-05-18 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
JP2010521450A (en) 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド Amino-pyridine derivatives as S1P1 / EDG1 receptor agonists
CN104478821B (en) * 2007-10-04 2016-09-28 默克雪兰诺有限公司 Oxadiazole diaryl compounds
WO2009080663A1 (en) * 2007-12-21 2009-07-02 Merck Serono S.A. Triazole oxadiazoles derivatives
CN102007107B (en) 2008-03-07 2014-07-23 埃科特莱茵药品有限公司 Novel aminomethyl benzene derivatives
JP2012515788A (en) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー Substituted oxadiazole derivatives as S1P agonists in the treatment of autoimmune and inflammatory diseases
CN102361868A (en) 2009-01-23 2012-02-22 百时美施贵宝公司 Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
US8354398B2 (en) 2009-01-23 2013-01-15 Bristol-Myers Squibb Company Substituted isoxazole compounds
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
GB0911130D0 (en) * 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
WO2010148649A1 (en) * 2009-06-26 2010-12-29 Glaxo Group Limited 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
SI2454255T1 (en) 2009-07-16 2014-01-31 Actelion Pharmaceuticals Ltd. Pyridin-4-yl derivatives as s1p1/edg1 agonists
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
EP2597089A1 (en) 2009-10-29 2013-05-29 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
MX2012005281A (en) 2009-11-05 2012-06-19 Fibrostatin S L Gpbp inhibition using q2 peptidomimetics.
JP2013522240A (en) * 2010-03-17 2013-06-13 グラクソ グループ リミテッド Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (S1P1) receptor agonists
EP2560969B1 (en) 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
EP2595969B1 (en) 2010-07-20 2015-04-22 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
JP5869579B2 (en) 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Substituted oxadiazole compounds and their use as S1P1 agonists
EP2635573B1 (en) 2010-11-03 2014-10-01 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
JP2014503501A (en) 2010-11-22 2014-02-13 アラーガン インコーポレイテッド Novel compounds as receptor modulators with therapeutic utility
PT2665720E (en) 2011-01-19 2015-09-16 Actelion Pharmaceuticals Ltd 2-METHOXY-PYRIDIN-4-ILO DERIVATIVES
EP2511275A1 (en) * 2011-04-12 2012-10-17 Bioprojet Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
CN102250035A (en) * 2011-06-10 2011-11-23 北京富卡生物技术有限公司 Synthesis method and medicinal purpose of diaryl substituted-1,3,4-oxadiazole compounds
UY35338A (en) 2013-02-21 2014-08-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware BICYCLIC COMPOUNDS MODULATING THE ACTIVITY OF S1P1 AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN105189487B (en) 2013-03-15 2017-12-26 爱杜西亚药品有限公司 The radical derivative of pyridine 4
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
WO2015134711A1 (en) 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
CA2990028A1 (en) * 2014-06-26 2015-12-30 Monash University Enzyme interacting agents
UY36274A (en) 2014-08-20 2016-02-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware BICYCLIC COMPOUNDS REPLACED AS SELECTIVE AGONISTS OF S1P1 RECEPTOR ACTIVITY COUPLED TO PROTEIN G
WO2016065583A1 (en) * 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Oxazole orexin receptor antagonists
KR20200044155A (en) 2015-05-20 2020-04-28 이도르시아 파마슈티컬스 리미티드 Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
CA3003132A1 (en) 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy
JP6192130B2 (en) * 2015-12-09 2017-09-06 株式会社大一商会 Game machine
JP2019516670A (en) * 2016-04-12 2019-06-20 シンジェンタ パーティシペーションズ アーゲー Microbicidal oxadiazole derivative
TW201808922A (en) 2016-06-20 2018-03-16 台灣神隆股份有限公司 Process for preparing ataluren and its intermediates
CN106279057B (en) * 2016-08-15 2022-04-15 广州明药科技有限公司 Synthetic method of Ataluren
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
CN109180439A (en) * 2018-10-22 2019-01-11 江苏长青农化股份有限公司 A kind of synthetic method of dicamba
CN109942382B (en) * 2019-04-24 2021-11-26 珠海市柏瑞医药科技有限公司 Method for synthesizing vanillyl alcohol ether
KR20230038457A (en) 2020-06-10 2023-03-20 알리고스 테라퓨틱스 인코포레이티드 Antiviral compounds for treating coronavirus, picornavirus and norovirus infections
KR20220055802A (en) * 2020-10-27 2022-05-04 서울대학교산학협력단 Composition for antioxidant, anti-inflammatory, and dementia prevention or improvement comprising protein expression inhibitor and use thereof
CN113754646B (en) * 2021-07-19 2023-07-25 安徽医科大学 (4-(1,2,4-oxadiazol-5-yl)phenyl)carboxamide derivatives and their application in anti-arthritic drugs
CN113651805B (en) * 2021-07-19 2023-07-25 安徽医科大学 1,2, 4-oxadiazole-pyridine compound and application thereof in treating Alzheimer's disease
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
CN115141120A (en) * 2022-06-30 2022-10-04 湖南大学 Electrooxidation preparation method of astallurens
CN116041277B (en) * 2023-01-18 2024-11-01 中国药科大学 Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4135910A (en) * 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
GB1584716A (en) * 1976-06-04 1981-02-18 Hoechst Ag Carboxylic fused furan derivatives and their use as optical brighteners
WO2000064927A1 (en) * 1999-04-27 2000-11-02 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
WO2005115382A1 (en) * 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for medicinal uses
WO2006131336A1 (en) * 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
WO2008023783A1 (en) * 2006-08-25 2008-02-28 Asahi Kasei Pharma Corporation Amine compound
WO2008037476A1 (en) * 2006-09-29 2008-04-03 Novartis Ag Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties
WO2008076356A1 (en) * 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
WO2008152149A1 (en) * 2007-06-15 2008-12-18 Bioprojet Novel dicarboxylic acid derivatives as s1p1 receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320801A1 (en) 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenyl-substituted 1,2,4-triazoles and 1,2,4-oxadiazoles, their use as pharmaceutical agents and pharmaceutical compositions containing them
PL3345895T3 (en) 2003-04-11 2020-05-18 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
EP1625123A4 (en) * 2003-05-15 2007-08-29 Merck & Co Inc 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
CN1859908A (en) 2003-10-01 2006-11-08 默克公司 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
WO2007043400A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated aromatic heterocyclic compound and pharmaceutical composition comprising the same
CN104478821B (en) 2007-10-04 2016-09-28 默克雪兰诺有限公司 Oxadiazole diaryl compounds

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1584716A (en) * 1976-06-04 1981-02-18 Hoechst Ag Carboxylic fused furan derivatives and their use as optical brighteners
US4135910A (en) * 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
WO2000064927A1 (en) * 1999-04-27 2000-11-02 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
WO2005115382A1 (en) * 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for medicinal uses
WO2006131336A1 (en) * 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
WO2008023783A1 (en) * 2006-08-25 2008-02-28 Asahi Kasei Pharma Corporation Amine compound
US20080200535A1 (en) * 2006-08-25 2008-08-21 Asahi Kasei Pharma Corporation Amine Compounds
WO2008037476A1 (en) * 2006-09-29 2008-04-03 Novartis Ag Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties
WO2008076356A1 (en) * 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
WO2008152149A1 (en) * 2007-06-15 2008-12-18 Bioprojet Novel dicarboxylic acid derivatives as s1p1 receptor agonists

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"CATALOG: New Chemistry Horizons Laboratories Building Blocks", 13 August 2007, NEW CHEMISTRY HORIZONS LABORATORIES LTD, MOSCOW *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002468003, retrieved from STN Database accession no. 2037051069 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 February 2005 (2005-02-17), XP002531331, retrieved from STN Database accession no. RN 832683-65-5 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 June 2007 (2007-06-17), XP002467995, retrieved from STN Database accession no. RN 937669-94-8 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 June 2007 (2007-06-17), XP002467996, retrieved from STN Database accession no. RN 937669-95-9 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 June 2007 (2007-06-17), XP002467997, retrieved from STN Database accession no. RN 937670-06-9 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 June 2007 (2007-06-17), XP002467998, retrieved from STN Database accession no. RN 937681-49-7 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 June 2007 (2007-06-17), XP002467999, retrieved from STN Database accession no. RN 937697-96-6 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 June 2007 (2007-06-17), XP002468000, retrieved from STN Database accession no. RN 937681-63-5 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 June 2007 (2007-06-17), XP002468001, retrieved from STN Database accession no. RN 937681-77-1 *
DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 19 July 2006 (2006-07-19), XP002531330, retrieved from STN Database accession no. RN 894518-34-4 *
L. YAN ET AL, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, 2006, pages 3679 - 3683, XP005477311 *
S.Y. CHO ET AL, BULL. KOREAN CHEM. SOC., vol. 24, no. 10, 2003, pages 1455 - 1464, XP002467994 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Also Published As

Publication number Publication date
ZA201104423B (en) 2012-03-28
EP2193125B1 (en) 2017-01-11
AU2008306885A1 (en) 2009-04-09
AU2008306885B2 (en) 2013-12-05
AR068731A1 (en) 2009-12-02
MX2010003612A (en) 2010-04-30
ES2622423T3 (en) 2017-07-06
WO2009043889A2 (en) 2009-04-09
KR20100075608A (en) 2010-07-02
EA201070422A1 (en) 2010-12-30
CA2696863C (en) 2016-10-18
CA2696863A1 (en) 2009-04-09
BRPI0818457A2 (en) 2015-04-14
JP6144450B2 (en) 2017-06-07
JP6148263B2 (en) 2017-06-14
CN101970420A (en) 2011-02-09
CN101970420B (en) 2014-09-24
ZA201001121B (en) 2011-10-26
JP2015063571A (en) 2015-04-09
US20100240658A1 (en) 2010-09-23
US8202865B2 (en) 2012-06-19
IL204521A0 (en) 2010-11-30
JP2010540592A (en) 2010-12-24
EP2193125A2 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
WO2009043889A3 (en) Oxadiazole derivatives
WO2010115751A3 (en) Oxadiazole derivatives
WO2010063700A3 (en) Novel pyrazole-4 -n-alkoxycarboxamides as microbiocides
WO2010139656A3 (en) Synergistic fungicidal mixtures
EA201070423A1 (en) DIARYLIC COMPOUNDS OF OXADIAZOLES
WO2009156462A3 (en) Organic compounds
WO2009024342A3 (en) Novel microbiocides
WO2007075869A3 (en) Bicyclic heteroaryl compounds
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2008118332A3 (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
WO2012061290A3 (en) Pesticidal compositions and processes related thereto
AU2010246102A8 (en) Pesticidal compositions
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
EA201070238A1 (en) PYRIMIDINE COMPOUNDS
WO2007100617A3 (en) Imidazole-based compounds, compositions comprising them and methods of their use
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2007133560A3 (en) Acetylenic heteroaryl compounds
EA201070779A1 (en) TRIAZOLE-CONTAINING OXADIAZOLE DERIVATIVES
WO2010068292A8 (en) Azaindole derivatives as kinase inhibitors
WO2007133562A3 (en) Monocyclic heteroaryl compounds
WO2009124962A3 (en) Sulfonamides
WO2008151828A3 (en) Novel microbiocides
WO2009127718A3 (en) Novel microbiocides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880110421.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08804970

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2696863

Country of ref document: CA

Ref document number: 2008306885

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1355/DELNP/2010

Country of ref document: IN

Ref document number: 12675235

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2008306885

Country of ref document: AU

Date of ref document: 20081001

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2008804970

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008804970

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 204521

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/003612

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010527449

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201070422

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20107009976

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0818457

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100401